Year: 2021

Figure 1White Gold Corp. VG Deposit Regional Location MapFigure 2White Gold Corp. VG Deposit Cross SectionFigure 3White Gold Corp. VG Deposit Isometrics of VG ZoneTORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company”) is pleased to announce an updated mineral resource estimate for the VG deposit on its QV project which is located approximately 85 km south of Dawson City and 11 km north of the Company’s flagship Golden Saddle and Arc deposits (Figure 1) which contain a combined mineral resource of 1,139,900 ounces Indicated at 2.28 g/t Au and 402,100 ounces Inferred at 1.39 g/t Au(1) in west-central Yukon, Canada. This work forms part of the Company’s fully funded 2021 exploration program backed by partners Agnico...

— Achieves Record Quarterly Revenues — MONTREAL, Nov. 11, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3 2021 Highlights FinancialsRevenues were $73,340, an increase of $28,101 or 62% over the same period in prior year. Gross margin of $37,766 or 51% compared to $19,533 or 43% in the same period in prior year. Adjusted EBITDA1 was $17,334, an increase of $13,118 or 311% over the same period in prior year. Net loss on financial assets measured at fair value through profit or loss of $21,301...

Please find enclosed Eika Boligkreditt AS’ interim report for the third quarter 2021. The report is also available on http://eikbol.no/AttachmentEika Boligkreditt AS – Report 3Q 2021

TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital”, “Flow”, or the “Company”) announces that it has a US$1.5M investment into Kovo HealthTech Corporation (“Kovo”). The investment is expandable to US$7M under certain conditions. Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for US healthcare clinics, hospitals and private practices. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way, using its proprietary OneRev technology platform. By offering effective billing practices and technology through long-term SaaS-style contracts, Kovo helps healthcare practitioners focus...

TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital”, “Flow”, or the “Company”) announces that it has closed the first tranche of an investment in VET24SEVEN, INC. (“AskVet”), a technology-based pet wellness platform. AskVet is an online/mobile pet wellness management platform that helps pet owners manage their pet’s daily health and wellness. AskVet is the first and only pet wellness management platform built on the belief that a pet’s lifestyle directly impacts their overall health and happiness. The company provides pet owners 24/7 virtual access to veterinarians and pet coaches for a personalized, guided experience that creates healthy habits and joyful pets. AskVet provides pet parents a team of experts to answer questions on anything from wellness, nutrition, and behavior to chronic...

10-count oral pack – or ‘X’ pack allows for improved access and the opportunity to further expand retail availability DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the oral formulation of XENLETA® (lefamulin) is now available in a 10-count oral pack in the U.S. through major specialty distributors. XENLETA is the first oral and IV treatment in the pleuromutilin class of antibiotics. XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP). XENLETA has a novel mechanism of action that targets a binding site...

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November:Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on Tuesday, November 16, 2021 at 10:20 a.m. ET Jefferies London Healthcare Conference available on-demand beginning Thursday, November 18, 2021 at 3:00 a.m. ET / 8:00 a.m. GMT Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 8:25 a.m. ETWebcasts of the presentations will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. Replays will be available for 30 days following the events. About Celldex Therapeutics, Inc.Celldex is a clinical...

Šiaulių Bankas shall publish the information to investors in 2022 in accordance with the following calendar:28/02/2022      –      Interim information for 12 months of 2021;02/03/2022      –      Investor Conference Webinar of introducing the financial results for the 2021;09/03/2022      –      Notice on convocation of the Ordinary General Shareholder Meeting (GSM), draft resolutions for the convened GSM;30/03/2022      –      Resolutions of the General Shareholder Meeting;30/03/2022      –      Audited annual information for 2021;29/04/2022      –      Interim information for 3 months of 2022;04/05/2022      –      Investor Conference Webinar of introducing the financial results for the 1 quarter of 2022;29/07/2022      –      Interim information for 6 months of 2022;03/08/2022      –     ...

Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021. The on-demand presentation will be available beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference. Enquiries:Silence Therapeutics plc Gem Hopkins,...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Analyst Event on November 18, 2021, from 12-2pm ET to highlight its clinical stage pipeline programs and the Axiomer® RNA editing platform. ProQR leadership will highlight key advancements from its clinical-stage pipeline, including data from the Phase 1/2 InSight extension study of sepofarsen. The Company will also highlight the sepofarsen program more broadly, recapping data from the program to date, sharing the perspective of a patient from the Phase 1/2 trial, and reviewing the Phase 2/3 Illuminate trial design and assumptions. The QR-421a, QR-1123, QR-504a,...